A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoparathyroidism

Interventions

DRUG: Palopegteriparatide

Sponsor

Ascendis Pharma A/S